Investor Presentation Full Year 2021
47
Investor presentation Full year 2021
Phase 3 trial programme, COMBINE, has been initiated with
icosema
IcoSema characteristics
名
Icosema is a fixed dose combination
of insulin icodec and semaglutide
• Simple and convenient once weekly
injection
کی
COMBINE 1
Post-basal insulin
COMBINE 2
Post-GLP-1
Phase 3a programme with icosema
initiated in Q4 2021
• Aims to confirm efficacy and safety
•
across three global trials
Expected completion during 2024
COMBINE 3
Basal insulin
intensification
*Patients with Type 2 Diabetes Mellitus
.
•
.
•
Focused phase 3 trial programme
•
•
•
•
1290 patients* previously on basal-insulin
52-week vs. insulin icodec
Prim. endpoint: HbA₁ superiority
Sec. endpoint: Weight and hypo superiority
680 patients* previously on GLP-1 RA
52-week vs. semaglutide 1.0mg
Primary endpoint: HbA1c superiority
680 patients* previously on basal insulin
52-week vs. insulin glargine + insulin aspart
Prim. endpoint: HbA1c non-inferiority
Sec. endpoint: Weight and hypo superiority
2021
2022
2023
2024
Novo NordiskⓇView entire presentation